Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVATAK Alone and with Mitomycin C in NMIBC
NCT02316171Phase 1Completed
- Sponsor
- Viralytics Ltd
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of coxsackievirus a21 in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Viralytics Ltd. Primary endpoint: Incidence of Dose-limiting Toxicities Treatment-related Adverse Events at 30 days. Started Jan 2015; status: completed.
02
Drugs
coxsackievirus a21
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02316171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316171.